Immunology Market Size to grow by USD 56.07 billion between 2023-2027
According to a research report “ Immunology Market” by Type (Immunosuppressants, Immuno boosters ) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies ) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2027 published by Technavio, the market size is estimated to grow by USD 56.07 billion, at a CAGR of 8.84% during the forecast period. The organ transplantation sector in the United States has experienced a noteworthy expansion, with 39,000 transplants carried out in 2020, as per the October 2021 report by the Office of Disease Prevention and Health Promotion (ODPHP). This figure represents a substantial 8.5% increase from the previous year. This growth can be attributed to the relentless dedication and collaborative efforts of organ procurement organizations, hospitals, and the Organ Procureation and Transplantation Network (OPTN). Given the upward trend in transplantations, the demand for immunosuppressive drugs is projected to surge, thereby fueling the expansion of the global immunology market throughout the forecast period.
Browse market data tables, figures, and in-depth TOC on “Immunology Market” by Type (Immunosuppressants, Immuno boosters ) Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies ) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2027. Download Free Sample
By Type, the Immunosuppressants segment is projected to dominate the market size in 2024
The global immunology market represents a significant and expanding business sector, offering a diverse array of products and services pertaining to the diagnosis, treatment, and prevention of immune system-related diseases. Hospital pharmacies hold a pivotal position within this industry, as they are instrumental in supplying patients with essential medications and related services. These pharmacies play a decisive role in the immunology market by managing the dispensation of medications for conditions such as rheumatoid arthritis, psoriasis, and multiple sclerosis. They maintain a comprehensive inventory of immunology drugs, including biologics, immunomodulators, and immunosuppressants. Hospital pharmacies foster close collaborations with healthcare professionals to ensure timely and accurate medication administration for their patients.
By Distribution Channel, Hospital pharmacies segment is expected to hold the largest market size for the year 2024
In the realm of healthcare, immunosuppressants, or anti-rejection drugs, play a pivotal role by moderating the body's immune response. These pharmaceuticals inhibit the immune system from recognizing and attacking foreign agents, such as transplanted organs or artificial joints. In organ transplantation, the body's defense mechanisms identify the new organ as a threat, triggering an immunological response that can lead to rejection. Immunosuppressants mitigate this response, preserving the graft and preventing potential damage to other bodily components. Additionally, individuals diagnosed with autoimmune disorders, including Chron's disease, irritable bowel syndrome, and arthritis, often rely on immunosuppressants to manage their conditions by suppressing their overactive immune systems.
North America is forecasted to hold the largest market size by region in 2024
The North American immunology market is poised for moderate growth during the forecast period, driven by significant investments from government and non-government entities, and the rising incidence of chronic diseases such as rheumatoid arthritis and cancer. Notably, the most prevalent cancers in North America include lung, breast, colon, and prostate cancer. For instance, the US Centers for Disease Control and Prevention (CDC) reported a female breast cancer incidence rate of 123.9 per 100,000 people in January 2021. Recent clinical trial findings suggest that the efficacy of anti-cancer drugs is enhanced when administered in conjunction with immuno-boosting agents.
The Immunology Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Immunology Market is a significant and rapidly growing sector within the healthcare industry, driven by advancements in Biotechnology and the increasing prevalence of Infectious diseases, Allergies, Cancer, and Autoimmune diseases. These conditions often involve Dysregulation of the Immune responses, leading to a need for innovative Diagnostic tools and Therapies. Biotechnology plays a crucial role in Immunology, with the development of Immune checkpoint inhibitors, PCR-based diagnostics, Flow cytometry, and ELISA assays, among others. Biological medications, such as Monoclonal antibodies, Biologics, Biosimilars, and Immune system modulators, are becoming increasingly important in the treatment of Immune-related disorders like Type 1 diabetes, Psoriatic arthritis, Rheumatoid arthritis, and various other Immunological disorders and Infections. Hospital pharmacies are key players in the distribution and administration of these advanced therapies. Innovative therapies like Immune response modulators and Immune checkpoint inhibitors are transforming the treatment landscape for various diseases, including Cancer and Autoimmune disorders. The market for these therapies is expected to grow significantly in the coming years, driven by the increasing prevalence of these conditions and the development of new and effective treatments.
Market Research Overview
The Immunology Market encompasses a range of innovative therapies and treatments, including gene editing techniques and gene therapies, targeted therapies, and precision medicine. Upadacitinib and Tofacitinib are notable Janus kinase inhibitors used in treating chronic inflammatory conditions such as psoriasis and rheumatoid arthritis. Reimbursement policies play a significant role in the market, with disease indications, drug classes, and treatment modalities influencing coverage. Allergies, autoimmune disorders, and cancer are dominant sectors, with immunological dysregulation driving the need for innovative therapies. Molecular biology and biotechnology have led to the development of monoclonal antibodies, adoptive cell therapies like CAR-T cell therapy, and immune checkpoint inhibitors. Reimbursement systems and diagnostic tools, such as PCR-based diagnostics, flow cytometry, and ELISA assays, are essential components of the market. Immunosuppressive substances, systemic medications, and immunomodulators are used to manage immune responses in various disease pathways. Biological medications and biosimilars, including Adalimumab, Rituximab, and Tumor Necrosis Factor-alpha inhibitors, play a significant role in treating conditions like inflammatory bowel disease, ankylosing spondylitis, plaque psoriasis, and rheumatoid arthritis. Side effects and disease pathways influence drug development and usage reviews, with pharmacists and academic institutions involved in drug schedules and clinical studies. Cancer immunotherapy, including radiation therapy, chemotherapy, and immunotherapies, targets cancer cells, viruses, microbes, and antigens. Precision medicine and personalized immunotherapies utilize biomarkers and molecular composition to tailor treatments for individual patients. The market includes online, retail, and hospital pharmacies, with prophylaxis and immunological disorders, such as autoimmune disorders, infections, and immune system components, also represented.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
